Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | F13A1 | P00488 | 2/20 | 0.43 |
| ▸ | TGM2 | P21980 | 2/20 | 0.43 |
| ▸ | TGM1 | P22735 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.41 |
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | CTSG | P08311 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6455119 | 0.87 | LSS (0.65) | LSSNPC1RAB9A | |
| SCHEMBL6450223 | 0.85 | LSS (0.64) | LSSSMN1; SMN2HTT | |
| SCHEMBL6448079 | 0.84 | LSS (0.60) | LSS | |
| SCHEMBL6450248 | 0.84 | LSS (0.63) | LSSF2 | |
| SCHEMBL4804179 | 0.84 | LSS (0.52) | LSSSIGMAR1 | |
| SCHEMBL4804176 | 0.84 | LSS (0.52) | LSSSIGMAR1 | |
| SCHEMBL6450962 | 0.83 | LSS (0.60) | LSSNPC1RAB9A | |
| SCHEMBL4805864 | 0.82 | LSS (0.50) | LSSF13A1TGM2TGM1 | |
| SCHEMBL4805861 | 0.82 | LSS (0.50) | LSSF13A1TGM2TGM1 | |
| SCHEMBL4802760 | 0.82 | LSS (0.50) | LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1231466-C | New piperidine derivatives | HOFFMANN LA ROCHE (CH) | 2005-12-14 | — | — | CN | disclosed |
| US-6964974-B2 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-11-15 | — | — | US | disclosed |
| CN-1468220-A | New piperidine derivatives | - | 2004-01-14 | — | — | CN | disclosed |
| EP-1317432-A1 | PIPERIDINE DERIVATIVES FOR USE AS 2,3-OXIDOSQUALENE-LANOSTEROL CYCLASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-11 | — | — | EP | disclosed |
| US-20020068753-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2002020483-A1 | PIPERIDINE DERIVATIVES FOR USE 2,3-OXIDOSQUALENE-LANOSTEROL CYCLASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068753-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | CYP51A1, LSS, CYP46A1 | LSS 2/4885SMN1; SMN2 4781/4885NPC1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.